Repurposing of Drugs Targeting YAP-TEAD Functions.
Gian Marco ElisiMatteo SantucciDomenico D'ArcaAngela LauriolaGaetano MarvertiLorena LosiLaura ScalviniMaria Laura BolognesiMarco MorMaria Paola CostiPublished in: Cancers (2018)
Drug repurposing is a fast and consolidated approach for the research of new active compounds bypassing the long streamline of the drug discovery process. Several drugs in clinical practice have been reported for modulating the major Hippo pathway's terminal effectors, namely YAP (Yes1-associated protein), TAZ (transcriptional co-activator with PDZ-binding motif) and TEAD (transcriptional enhanced associate domains), which are directly involved in the regulation of cell growth and tissue homeostasis. Since this pathway is known to have many cross-talking phenomena with cell signaling pathways, many efforts have been made to understand its importance in oncology. Moreover, this could be relevant to obtain new molecular tools and potential therapeutic assets. In this review, we discuss the main mechanisms of action of the best-known compounds, clinically approved or investigational drugs, able to cross-talk and modulate the Hippo pathway, as an attractive strategy for the discovery of new potential lead compounds.
Keyphrases
- drug discovery
- clinical practice
- signaling pathway
- gene expression
- transcription factor
- small molecule
- palliative care
- drug induced
- cell therapy
- cancer therapy
- nuclear factor
- drug delivery
- risk assessment
- heat shock
- oxidative stress
- pi k akt
- climate change
- single molecule
- type iii
- drug administration
- induced apoptosis
- endoplasmic reticulum stress
- heat shock protein
- electronic health record
- adverse drug
- toll like receptor